Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:42:44.016Z.
Calculation as of: 2026-10-06T20:42:44.016Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b1195b951add05ab4c37664b10382d427b1d38f05de7a164f71fe4d518fffb76
PE RATIO
N/A
Market Cap
$82.53M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.61M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ProMIS Neurosciences, Inc. (PMN) | $82.59M | N/A | N/A | N/A | N/A |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | N/A | N/A | N/A | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | N/A | N/A | N/A | N/A |
| LENSAR Inc (LNSR)vs › | $82.29M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $81.22M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.20M | N/A | N/A | N/A | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $80.30M | N/A | 8.03 | 8.03 | 8.03 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $79.61M | N/A | N/A | N/A | N/A |
| PMV Pharmaceuticals, Inc. (PMVP)vs › | $85.86M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
